234 related articles for article (PubMed ID: 29345426)
1. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
3. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
5. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
[TBL] [Abstract][Full Text] [Related]
6. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
7. Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
Anker SD; Ponikowski P; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Metra M; Piña IL; Coats AJS; Rosano G; Dorigotti F; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Butler J
Eur J Heart Fail; 2022 May; 24(5):833-842. PubMed ID: 35334136
[TBL] [Abstract][Full Text] [Related]
8. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
Jankowska EA; Kirwan BA; Kosiborod M; Butler J; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Filippatos G; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Friede T; Fabien V; Dorigotti F; Pocock S; Ponikowski P
Eur Heart J; 2021 Aug; 42(31):3011-3020. PubMed ID: 34080008
[TBL] [Abstract][Full Text] [Related]
9. Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Mentz RJ; Ambrosy AP; Ezekowitz JA; Lewis GD; Butler J; Wong YW; De Pasquale CG; Troughton RW; O'Meara E; Rockhold FW; Garg J; Samsky MD; Leloudis D; Dugan M; Mundy LM; Hernandez AF;
Circ Heart Fail; 2021 May; 14(5):e008100. PubMed ID: 34003690
[TBL] [Abstract][Full Text] [Related]
10. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
[TBL] [Abstract][Full Text] [Related]
12. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J;
Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528
[TBL] [Abstract][Full Text] [Related]
13. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
14. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
Butler J; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Dorigotti F; Metra M; Piña IL; Coats AJS; Rosano G; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Anker SD; Ponikowski P
Eur J Heart Fail; 2022 May; 24(5):821-832. PubMed ID: 35279929
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
16. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
[TBL] [Abstract][Full Text] [Related]
18. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
[TBL] [Abstract][Full Text] [Related]
19. The importance of dose optimisation in the treatment of iron deficiency in heart failure.
Martens P; Minten L; Dupont M; Mullens W
Acta Cardiol; 2020 Oct; 75(6):520-524. PubMed ID: 31184977
[No Abstract] [Full Text] [Related]
20. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
